



## **SciGen Announces the Official Opening of its Vaccine Manufacturing Facility**

**11<sup>th</sup> January 2007:** SciGen Limited (ASX: SIE) announces the official opening of its vaccine manufacturing facility in Israel. This facility will be supplying SciGen third generation hepatitis B vaccine, Sci B Vac™, to its distributors in Europe and the Asia Pacific region. Expansion of its facility is already in late stage planning and is expected to be completed by the end of 2007.

The manufacturing facility was built in close consultation with health regulatory agencies and speedy approval from the EMEA in Europe and the FDA is expected.

The opening of the manufacturing facility is a major event for SciGen and will greatly enhance SciGen's market penetration in this vaccine segment of over US\$1.2 Billion dollars worldwide.

### **About Sci B Vac™:**

Sci B Vac™ is a third generation recombinant hepatitis B Vaccine produced by Chinese Hamster ovary cells. Sci B Vac™ contains immunogenic regions of the three surface proteins of HBV.

Sci B Vac™ is a unique hepatitis B vaccine, which has repeatedly been shown to be highly immunogenic and safe in neonates, children and adults alike.

Worldwide sales of hepatitis B vaccines are estimated to be US\$1.2 billion.

### **About SciGen:**

SciGen Ltd is a biopharmaceutical company involved in commercializing later stage research. It co-develops and markets biopharmaceutical products for human healthcare. SciGen focuses in the areas of gastroenterology, endocrinology and immunology. Its product portfolio includes vaccines and therapeutics.

SciGen acquires rights to manufacture, distribute and market biopharmaceutical products under exclusive licensing arrangements. SciGen's portfolio currently includes proprietary biotechnology-derived products, and Biosimilar products, which allow for faster entry into the market, as Biosimilar products have undergone much of the clinical development and trials required to bring drugs to market. This minimizes the risks associated with early stage product development. SciGen currently undertakes R&D activities in collaboration with strategic partners and institutions.

SciGen's competitive advantage is in identifying research with commercial potential at an early stage to which it adds its expertise in clinical development, gaining regulatory approval and bringing products to market.

SciGen is a Singaporean biotechnology company, established in 1988 and listed on the Australian Stock Exchange (ASX code SIE). SciGen is headquartered in Singapore, with subsidiary companies in the USA, Australia, S. Korea, Hong Kong, Philippines, Vietnam, Israel and India, a Joint Venture in China, commercial partners in Europe and collaborative partners in the USA and the Netherlands



**Further information:**

Company – Investor Relations	Company
Ms. Maria Arroyan SciGen Australia +61 2 9234 1700 email: mariaaroyan@scigen.com.au	Saul Mashaal Chairman, Founder & CEO SciGen Ltd. + 61 2 9234 1700 +65 9630 5691 (Mobile)